ENTRY       D09669                      Drug
NAME        Siltuximab (USAN/INN);
            Sylvant (TN)
PRODUCT     SYLVANT (EUSA Pharma (UK))
FORMULA     C6450H9932N1688O2016S50
EXACT_MASS  144891.2586
MOL_WEIGHT  144981.2251
SEQUENCE    (Heavy chain)
            EVQLVESGGK LLKPGGSLKL SCAASGFTFS SFAMSWFRQS PEKRLEWVAE ISSGGSYTYY
            PDTVTGRFTI SRDNAKNTLY LEMSSLRSED TAMYYCARGL WGYYALDYWG QGTSVTVSSA
            STKGPSVFPL APSSKSTSGG TAALGCLVKD YFPEPVTVSW NSGALTSGVH TFPAVLQSSG
            LYSLSSVVTV PSSSLGTQTY ICNVNHKPSN TKVDKKVEPK SCDKTHTCPP CPAPELLGGP
            SVFLFPPKPK DTLMISRTPE VTCVVVDVSH EDPEVKFNWY VDGVEVHNAK TKPREEQYNS
            TYRVVSVLTV LHQDWLNGKE YKCKVSNKAL PAPIEKTISK AKGQPREPQV YTLPPSRDEL
            TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTTPPVL DSDGSFFLYS KLTVDKSRWQ
            QGNVFSCSVM HEALHNHYTQ KSLSLSPGK
            (Light chain)
            QIVLIQSPAI MSASPGEKVT MTCSASSSVS YMYWYQQKPG SSPRLLIYDT SNLASGVPVR
            FSGSGSGTSY SLTISRMEAE DAATYYCQQW SGYPYTFGGG TKLEIKRTVA APSVFIFPPS
            DEQLKSGTAS VVCLLNNFYP REAKVQWKVD NALQSGNSQE SVTEQDSKDS TYSLSSTLTL
            SKADYEKHKV YACEVTHQGL SSPVTKSFNR GEC
            (Disulfide bridge: H22-H96, H146-H202, H263-H323, H369-H427, H228-H'228, H231-H'231, L23-L87, L133-L193, H222-L213)
  TYPE      Peptide
CLASS       Immunological agent
             DG02019  Interleukin inhibitor
REMARK      ATC code: L04AC11
            Product: D09669<US>
EFFICACY    Immunomodulator, Anti-IL-6 antibody
  DISEASE   Castleman's disease [DS:H01479]
  TYPE      Monoclonal antibody
TARGET      IL6 [HSA:3569] [KO:K05405]
  PATHWAY   hsa04060(3569)  Cytokine-cytokine receptor interaction
            hsa04630(3569)  JAK-STAT signaling pathway
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
              L04 IMMUNOSUPPRESSANTS
               L04A IMMUNOSUPPRESSANTS
                L04AC Interleukin inhibitors
                 L04AC11 Siltuximab
                  D09669  Siltuximab (USAN/INN) &lt;US&gt;
            USP drug classification [BR:br08302]
             Immunological Agents
              Immunological Agents, Other
               Interleukin Blockers
                Siltuximab
                 D09669  Siltuximab (USAN/INN)
            Drug groups [BR:br08330]
             Immunological agent
              DG02019  Interleukin inhibitor
               D09669  Siltuximab
            Drug classes [BR:br08332]
             Immunological agent
              DG02019  Interleukin inhibitor
               D09669  Siltuximab
            Target-based classification of drugs [BR:br08310]
             Cytokines and receptors
              Cytokines
               Interleukins
                IL6
                 D09669  Siltuximab (USAN/INN) &lt;US&gt;
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D09669
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D09669
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D09669
DBLINKS     CAS: 541502-14-1
            PubChem: 124490409
///
